Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program

SYN-001Positive

AI Analysis

Summary

Synaptiq Therapeutics was formed to acquire and advance SYN-001, an FDA-designated orphan and rare pediatric disease therapeutic candidate, from Nobias Therapeutics. A Phase IIb trial is planned to evaluate SYN-001 for treating neuropsychiatric symptoms in 22q11.2 Deletion Syndrome.

Clinical Trial Data

Phase

IIb

Outcome Details

Synaptiq Therapeutics formed to advance SYN-001 program acquired from Nobias Therapeutics

Importance:6/10

Sentiment:

0.60

acquisitionorphan drugrare pediatric diseaseneuropsychiatricPhase IIb22q11.2 Deletion Syndrome

Read the original article

Published by PR Newswire Clinical Trials on July 23, 2026 12:56 PM

Read Original